MARKET

CDXS

CDXS

Codexis Inc
NASDAQ
3.510
+0.060
+1.74%
Closed 17:27 03/27 EDT
OPEN
3.460
PREV CLOSE
3.450
HIGH
3.585
LOW
3.450
VOLUME
497.24K
TURNOVER
0
52 WEEK HIGH
4.910
52 WEEK LOW
1.450
MARKET CAP
246.77M
P/E (TTM)
-3.1367
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CDXS last week (0318-0322)?
Weekly Report · 3d ago
AQST,CDXS and STI are among after hour movers
On the Move AQST,CDXS and STI are among after hour movers. Taysha Gene Therapies (TSHA) and Canopy Growth Corporation (CGC) are among Gainers. Aquestive Therapeutics (AQST) is among the losers.
Seeking Alpha · 03/19 21:37
Weekly Report: what happened at CDXS last week (0311-0315)?
Weekly Report · 03/18 09:19
Weekly Report: what happened at CDXS last week (0304-0308)?
Weekly Report · 03/11 09:19
Weekly Report: what happened at CDXS last week (0226-0301)?
Weekly Report · 03/04 09:19
Benchmark raises Codexis to buy; cites Q4 earnings, guidance
Healthcare Benchmark raises Codexis to buy; cites Q4 earnings, guidance. The company is slated to launch its ecoRNA ligase in the first half of 2024. Benchmark set its price target for Codexis at $9. The investment firm cites the company's positive Q4 Earnings report and guidance.
Seeking Alpha · 03/01 20:37
Piper Sandler Sticks to Their Buy Rating for Codexis (CDXS)
TipRanks · 03/01 12:48
A New Cause for Concern: Codexis Adds a New Corporate Activity and Growth Risk
TipRanks · 03/01 06:00
More
About CDXS
Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.

Webull offers Codexis Inc stock information, including NASDAQ: CDXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDXS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CDXS stock methods without spending real money on the virtual paper trading platform.